Aktana Acquires Tact.ai’s Field Engagement and Conversational AI Technology
Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, today announced the acquisition of Tact.ai’s field engagement and conversational AI technology. The addition extends Aktana’s leadership in field intelligence by delivering several new capabilities frequently requested by commercial and medical leaders overseeing omnichannel programs:
- Real-time delivery of suggestions and insights on the mobile phone
- Pervasive and on-demand recommendations throughout the user experience, including a conversational AI assistant
- Richer engagement data to improve AI recommendations
“Today’s sales rep or MSL is being asked to do more in less time and with fewer resources than ever before, and they need immediate access to the best intelligence on their most preferred device, the mobile phone,” said John Vitalie, CEO, Aktana. “Adding aspects of Tact.ai’s mobile technology and easy-to-use interface to the Aktana portfolio will accelerate our customers’ efforts to create the next-generation field force, one that’s powered by intelligence and adept at using any channel to support their HCPs.”
“Tact.ai set out to build human-friendly technology that connects life science companies and their customers, to help patients who can't wait,” said Chuck Ganapathi, CEO, Tact.ai. “Critical to that mission is a system of intelligence that fuels every interaction. As the pioneer of this category and with Tact.ai’s technology, Aktana is now even better positioned to lead this journey toward the future of customer engagement.”
Introducing Aktana Copilot
Powered by Tact.ai technology, Aktana today announced Aktana Copilot, an AI assistant on the mobile phone for life sciences field users. Specifically designed for the needs of field sales representatives and medical science liaisons, Aktana Copilot puts market and HCP intelligence in the hands of those users at the moment they need it.
Field teams will receive programmable and intelligence-driven nudges in real-time on mobile devices to simplify call planning with curated insights to drive more personalized and coordinated activity. In addition, recommendations will be presented through conversational AI throughout the user experience saving valuable time that can be repurposed for HCP relationship-building.
Through Aktana Copilot, customers can capture richer and more tailored engagement data which enables Aktana AI to produce more contextual and effective recommendations for users to have better conversations. The dynamic feedback loop improves time-to-value because as the speed in which recommendations improve accelerates, so too does campaign performance.
“Today’s announcements deepen our commitment to transforming customer engagement programs for life sciences organizations of all sizes,” said Derek Choy, founder and Chief Product Officer, Aktana. “The Strategy Suite that we unveiled at the Aktana Innovation Exchange last month will be enhanced with Aktana Copilot, providing a real-time connection between commercial leaders and the field. This can be used to get feedback from the field on tactics impacting their HCPs, and to nudge the field on tactics proven to have the highest impact.”
Aktana Copilot is available globally today and will be enhanced for specific use cases across commercial pharma, medical affairs and medical devices throughout 2024. Aktana will also offer Microsoft Teams users a version of Tact Presenter which is the only Microsoft Teams certified remote detailer for Veeva content.
Connect with Aktana on LinkedIn: www.linkedin.com/company/aktana
Follow @aktana_inc on Twitter: www.twitter.com/aktana_inc
About Aktana
Aktana is the leader in intelligent customer engagement for the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 350 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the world’s top 20 pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more, visit www.aktana.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231101732293/en/
Contact information
Debby Fry Wilson
deborah.wilson@aktana.com
425-638-9617
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press Release
1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi
Dompé Doses First Patients in Europe and US in Phase 3 Study of Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press Release
Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment to groundbreaking science with the potential for life-changing patient impact,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “The dual mechanism of isocyclosporin has the potential to redefine treatment and quality of life for patients living with poorly managed AKC. It also marks an important
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press Release
Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain developed by Circle (currently in public testnet). Arc’s purpose-built design offers the performance and scalability
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press Release
Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of annual net turnover. SWIFT SRG 2025 is another seismic update, representing the
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press Release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom